Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;50(8):892-923.
doi: 10.1111/hepr.13504. Epub 2020 Jul 15.

Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update

Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology

Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update

Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Hepatol Res. 2020 Aug.

Abstract

The Drafting Committee for Hepatitis Management Guidelines established by the Japan Society of Hepatology published the first version of the Guidelines for the Management of Hepatitis B in 2013 (first English version in 2014), and has since been publishing updates to the Guidelines as new drugs become available, with the latest original Japanese version being Version 3.1. Herein, the Drafting Committee publishes the second English version that contains all the changes made since the first English version of the guidelines was published in 2014. This 2019 version covers: (i) the nucleos(t)ide analogs, tenofovir disoproxil fumarate and tenofovir alafenamide; (ii) updates to treatment recommendations and management of drug-resistant hepatitis B virus that reflect the new availability of these drugs; and (iii) new information about hepatitis B virus reactivation with each update. This latest update also contains information about treatment goals, indications for treatment and cessation of nucleos(t)ide analog therapy, most of which were covered by the first version.

Keywords: antiviral treatment; drug resistance; hepatocellular carcinoma; tenofovir alafenamide; tenofovir disoproxil fumarate.

PubMed Disclaimer

References

    1. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res 2014; 44(Suppl S1): 1-58.
    1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
    1. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
    1. Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
    1. Koike K, Suyama K, Ito H, Itoh H, Sugiura W. Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients. Hepatol Res 2018; 48: 59-68.

LinkOut - more resources